Journal of Chemical Information and Modeling · 2020 · 20 citations · 160 references
MedicineOncologyPharmacologyChemotherapyDrug DesignDrug DiscoveryComputational Drug DiscoveryComputational OncologyLigand-based DesignMolecular DockingProtein-ligand DockingTopoisomerase InhibitorsAnticancer ActivityAnticancer ChemotherapyComputer-aided Drug DiscoveryDocking-based Drug DesignLigand Binding AffinityStructure-activity Relationship ModelingTopoisomerase Ii FunctionTopoisomerase Ii Inhibitors
Topoisomerase II (TopoII) is an enzyme essential for cellular metabolism and replication as it regulates DNA topology. Since inhibition of TopoII induces cell death, it is a well-established drug target in cancer therapy; several broadly used anticancer drugs including etoposide and doxorubicin are TopoII inhibitors. However, these therapeutics tend to cause severe side effects and suffer from relatively low ligand affinity, leaving TopoII targeting with small molecules an active area of research. In recent years computer-aided drug discovery (CADD) approaches have been actively used to expand knowledge on the role of TopoII in cancer and to develop novel strategies for its inhibition. Herein, we overview studies that employed structure-based approaches such as docking and molecular dynamic simulations, as well as ligand-based approaches, such as QSAR (quantitative structure-activity relationship) modeling among others, to gain understanding in TopoII targeting with existing drugs and to search for novel drug candidates.
160
GROMACS: Fast, flexible, and free
David van der Spoel, Erik Lindahl, Berk Hess et al. · Journal of Computational Chemistry · 2005 · 19.1K citations
Natural Sciences, Chemistry, Physics +17